The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

Colon Cancer Clinical Trial

Official title:

The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02052557
• Other study ID #: MMC2013-09
• Status: Completed
• Phase: Phase 4
• Start date: February 2013
• Est. completion date: December 2013

Study information

• Verified date: December 2020
• Source: Des Moines University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.

Description:

Patients who are undergoing elective colon resection with Dr. Kraemer and Dr. Raman will be offered participation in the study. This will include robotic, laparoscopic and open procedures.

In the pre-operative area prior to surgery, the surgical resident will inform the patient of the opportunity to participate in the research study. The resident will consent the patient at that time, if the patient chooses to participate, they will be randomized to an exparel or non-exparel group. The randomization will be done by having the resident pick an envelope that will state whether or not the patient is randomized to the exparel or non-exparel group, this will randomize to 50% in each group. The patient will not be notified of the type of local anesthetic they receive. The attending surgeon will also be blind to the type of local the pt will receive; only the resident and Operating Room (OR) staff will know what type of local anesthetic was given. Unfortunately the opaque color of the exparel precludes the physician injecting the local anesthetic from being blinded to the type of anesthetic given.

The patient will be taken to the operating room as usual, and the surgery will proceed as it normally would. At the end of the surgery the patient will receive either exparel or bupivacaine depending upon which the patient was randomized to. The attending surgeon will not be in the operating suite while the local anesthetic is being injected. 30 milliliters (mL) of either exparel or bupivacaine will be injected into the subcutaneous tissues at the end of surgery.

The patient will be taken to the post operative care unit (PACU), the medications for post-operative pain will be standardized between the two groups, a standard starting dose on the patient controlled analgesia (PCA) will be used, and will be adjusted as needed. The postoperative care will attempt to be standardized in regard to diet, discharge (dc) of foley, not using nasogastric (NG) tubes, however this will be based on the individual patient was what is best for their care. This data will then be analyzed to determine if exparel has a beneficial effect on surgical care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Elective colon resection for both benign and malignant disease

• Laparoscopic, robotic and open techniques

Exclusion Criteria:

• emergent colon cases

• cases preformed by surgeons other than Dr. Raman or Dr. Kraemer

• pregnant patients

• patients currently breast feeding

• patients under the age of 18

• other patients unable to give informed consent

• bupivacaine use within 96 hours

• allergy to amide anesthetics

• prisoners

• caution will be used in patients with renal or hepatic failure.

Related Conditions & MeSH terms

• Colon Cancer
• Diverticulitis
• Pain, Postoperative
• Post-operative Pain

Intervention

Drug:
• Bupivacaine
30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
• Bupivacaine liposome suspension
30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR

Locations

Country	Name	City	State
United States	Mercy Medical Center	Des Moines	Iowa

Sponsors (2)

Lead Sponsor	Collaborator
Des Moines University	Mercy Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	NG (Nasogastric) Placement	We recorded if an NG was placed immediately post operatively	POD #0 if NG was placed
Primary	PCA (Patient Controlled Analgesia) Usage	Will measure the amount of PCA use for the first 48 hours after surgery.	48 hours post operatively
Secondary	Oral Pain Medications	the amount of post operative oral narcotic is measured post op	48 hours postoperatively
Secondary	Total IV (Intravenous) Narcotic Used	the total amount of IV narcotic is measured that is given during post op period prior to discharge	participants will be followed for the duration of hospital stay, an expected average of 3 days
Secondary	Total Oral Narcotic Used		participants will be followed for the duration of hospital stay, an expected average of 3 days
Secondary	Length of Stay		participants will be followed for the duration of hospital stay, an expected average of 3 days
Secondary	Return of Bowel Function		participants will be followed for the duration of hospital stay, an expected average of 3 days, and the timing of return of bowel function returning will be recorded
Secondary	Readmission		30 days post operative readmission
Secondary	Toradol Use		participants will be followed for the duration of hospital stay, an expected average of 3 days
Secondary	Ofirmev		participants will be followed for the duration of hospital stay, an expected average of 3 days, and the amount of ofirmev used during admission will be recorded
Secondary	Nausea Medication		The amount of nausea medicine used 48 hours post op was recorded
Secondary	Foley Catheter Removal		participants will be followed for the duration of hospital stay, an expected average of 3 days, the timing of foley catheter removal will be recorded
Secondary	Postoperative Pain	The investigators will talk to the patient after surgery immediately post operatively Post Operative Day (POD) #3-5 and POD #13-15 and ask the patients to rate their pain on a scale of 1-10.	POD #3-5 and POD #13-15
Secondary	Post Operative Satisfaction	The investigators will ask the patient to rate their satisfaction with pain control.	POD #3-5 and POD #13-15
Secondary	Home Oral Narcotic Use	The investigators will ask the patients how many of their narcotic pain pills they used after surgery up to the POD #13-15	POD #13-15